What are GLP-1 drugs?

GLP-1 drugs are a class of medications used for type 2 diabetes and obesity, mimicking a natural hormone that lowers blood sugar and aids weight loss.

What is Amgen's competitive advantage?

Amgen's advantage lies in its diversified drug portfolio, reducing reliance on the GLP-1 market, plus its experimental drug MariTide which could be a strong competitor.

Does the analysis recommend buying either stock?

No, the analysis is neutral and does not provide a buy or sell recommendation; it offers a comparison to help investors decide.

Novo Nordisk vs. Amgen: Which Pharma Stock Is Better?

Zacks analysis compares Novo Nordisk (NVO) and Amgen (AMGN) in the GLP-1 space, weighing market leadership, pipeline strength, and diversification to help investors decide.

According to an analysis by Zacks, two pharma stocks are competing in the GLP-1 drug market for diabetes and obesity: Novo Nordisk (NVO) and Amgen (AMGN). The analysis aims to help investors evaluate which might be the better pick.

GLP-1 Market Leadership

Novo Nordisk currently dominates the GLP-1 market with its blockbuster drugs Ozempic and Wegovy, giving it a clear lead. Amgen is playing catch-up with its experimental drug AMG 133 (MariTide), which has shown promising clinical trial results.

Pipeline Strength

Novo Nordisk: Has a robust pipeline including oral GLP-1 formulations (e.g., oral semaglutide) and label expansions.
Amgen: Focuses on MariTide plus earlier-stage assets, but lacks an approved GLP-1 product currently.

Diversification

Amgen boasts a diversified portfolio spanning oncology, bone disease, and inflammation drugs, reducing its reliance on GLP-1. In contrast, Novo Nordisk is heavily dependent on diabetes and obesity drugs, making it more vulnerable to market shifts.

Financial Performance

The analysis did not cite specific financial figures but noted both companies have strong fundamentals. However, Novo Nordisk's valuation may be elevated relative to Amgen's.

What to Conclude

The analysis offers a neutral comparison without a buy or sell recommendation. Investors seeking direct GLP-1 exposure may lean toward Novo Nordisk, while those preferring lower-risk diversification might favor Amgen.